NCT06621082View on ClinicalTrials.gov

The Clinical Study of the Treatment of Patients With Type I Neurofibromatosis With Smetinib Hydrosulfate Capsule

PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

September 30, 2024

Primary Completion Date

November 30, 2026

Study Completion Date

December 31, 2026

Conditions

Neurofibromatosis 1

Interventions

DRUG

Selumetinib

After surgical resection，based on the patient's body surface area (BSA), the patient was given an oral dose of Simetinib bisulfate capsule (20-50mg bid) daily for 30 days for 6 cycles

All Listed Sponsors

lead

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

OTHER

NCT06621082 - The Clinical Study of the Treatment of Patients With Type I Neurofibromatosis With Smetinib Hydrosulfate Capsule | Biotech Hunter | Biotech Hunter